Maven Securities LTD Buys 5,000 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Maven Securities LTD increased its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 33.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 20,000 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Maven Securities LTD’s holdings in Inari Medical were worth $963,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Inari Medical by 11.1% in the 1st quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock worth $268,681,000 after buying an additional 561,562 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of Inari Medical by 113.3% in the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock worth $71,324,000 after purchasing an additional 786,691 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Inari Medical by 353.1% in the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after acquiring an additional 786,501 shares in the last quarter. American Century Companies Inc. increased its holdings in Inari Medical by 26.8% in the 2nd quarter. American Century Companies Inc. now owns 980,917 shares of the company’s stock valued at $47,231,000 after acquiring an additional 207,485 shares during the last quarter. Finally, Bamco Inc. NY boosted its position in shares of Inari Medical by 27.4% during the 1st quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock valued at $37,288,000 after acquiring an additional 167,000 shares during the last quarter. 90.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NARI has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft started coverage on Inari Medical in a research report on Friday, August 9th. They set a “buy” rating and a $68.00 target price on the stock. Truist Financial reiterated a “hold” rating and set a $55.00 price objective (down previously from $60.00) on shares of Inari Medical in a research note on Wednesday, July 31st. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Wednesday, July 31st. Canaccord Genuity Group increased their price objective on shares of Inari Medical from $55.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, Wells Fargo & Company dropped their price objective on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Inari Medical has a consensus rating of “Hold” and an average target price of $58.44.

Inari Medical Stock Down 1.5 %

NASDAQ:NARI opened at $40.63 on Wednesday. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $69.40. The company has a market capitalization of $2.36 billion, a PE ratio of -99.10 and a beta of 1.00. The stock has a fifty day simple moving average of $46.32 and a 200-day simple moving average of $46.12.

Inari Medical (NASDAQ:NARI) last released its earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.25). The business had revenue of $145.82 million for the quarter, compared to analysts’ expectations of $143.96 million. Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%. As a group, equities analysts anticipate that Inari Medical, Inc. will post -0.7 earnings per share for the current year.

Insider Buying and Selling

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now directly owns 643,296 shares in the company, valued at approximately $29,482,255.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Mitch C. Hill sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the sale, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,105,348. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the sale, the director now directly owns 643,296 shares of the company’s stock, valued at $29,482,255.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 132,520 shares of company stock valued at $6,958,467. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.